Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

182.15 -7.11 (-3.76%)
Delayed Quote Updated: 10:49 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead ↗
Innovation pays off. 
Via The Motley Fool
News headline image
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? ↗
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead. 
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗
Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence. 
Via The Motley Fool
Revolution Medicines (NASDAQ:RVMD) Misses Q2 Estimates, Yet FDA Accepts Daraxonrasib Application ↗
Via Chartmill
Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup ↗
Via Chartmill
News headline image
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? ↗
This company has succeeded where many others have failed. 
Via The Motley Fool
News headline image
MarketBeat Week in Review – 09/07 - 09/11 ↗
Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and... 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years. 
Via The Motley Fool
News headline image
Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus. 
Via MarketBeat
News headline image
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today ↗
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines has a... 
Via Benzinga
News headline image
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer ↗
Revolution Medicines (NASDAQ:RVMD) said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma. The... 
Via MarketBeat
News headline image
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? ↗
The biotech's Rasonque is already available for prescription. 
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today ↗
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an annualized basis producing an average annual return of 49.25%. Currently, Revolution Medicines has a... 
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? ↗
One of the most successful investors ever really likes this up-and-coming biotech stock. 
Via The Motley Fool
News headline image
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗
Could these 2 stocks outperform most GLP-1-focused companies over the medium term? 
Via The Motley Fool
News headline image
Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks ↗
Small-cap stocks are finally recovering after years of underperforming the major indexes. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript ↗
Biotech advances RAS-inhibitor pipeline with $3.9B cash and FDA acceptance of daraxonrasib NDA. 
Via The Motley Fool
Topics Earnings
News headline image
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years ↗
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an annualized basis producing an average annual return of 49.88%. Currently, Revolution Medicines has a... 
Via Benzinga
News headline image
Revolution Medicines Q2 Earnings Call Highlights ↗
Revolution Medicines (NASDAQ:RVMD) said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it... 
Via MarketBeat
Topics Earnings
News headline image
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy? ↗
This billionaire investor is betting big on a revolutionary approach in treating pancreatic cancer. 
Via The Motley Fool
News headline image
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock ↗
The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials. 
Via The Motley Fool
News headline image
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗
But is that performance sustainable? 
Via The Motley Fool
News headline image
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It ↗
Revolution Medicines could be a revolutionary biotech stock. 
Via The Motley Fool
News headline image
Better Growth Buy: Axsome vs Revolution Medicines ↗
These stocks both scored a win in the first half of the year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗
These stocks have jumped in the double- and triple-digits. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? ↗
The company recently wowed investors with clinical trial results. 
Via The Motley Fool
News headline image
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. ↗
This pre-commercial biotech is worth more than some drugmakers that generate consistent sales. 
Via The Motley Fool
News headline image
Can Revolution Medicines Be a Game-Changer Stock? ↗
This company's potential pancreatic cancer blockbuster could be a watershed moment. 
Via The Motley Fool
News headline image
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗
Can the drugmaker justify its valuation? 
Via The Motley Fool
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.